Novel heteroaryl-substituted acetone derivatives as inhibitors of phospholipase a2

Compounds of formula I

• wherein
• Q represents R1, OR1, SR1, SOR1, SO2R1, NR9R1 or a straight-chain C1-31 alkyl or C2-31 alkenyl or alkinyl residue which may be interrupted by 1 or 2 residues, independently selected from O, S, SO, SO2, NR9 and aryl which may be substituted with 1 or 2 substituents R4, and which may be substituted with 1-4 C1-6 alkyl residues and/or 1 or 2 aryl residues, wherein the aryl residues may be substituted with 1 or 2 substituents R4;
• Ar represents an aryl residue which may be substituted with 1 or 2 substituents R4;
• X represents N or CR5;
• Y represents N or CR6;
• R1 represents H or an aryl residue which may be substituted with 1 or 2 substituents R4;
• R2 and R3 a) independently may stand for H, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl or R7—W, or b) together with the carbon atoms to which they are bound, form a 5- or 6-membered aromatic or heteroaromatic ring which may be substituted with 1 or 2 substituents R4;
• R4 represents C1-6 alkyl, halogen, CF3, CN, NO2, OR9, S(O)oR9, COR9, COOR9, CONR9R10, SO3R9, SO2NR9R10, tetrazolyl or R7—W;
• R5 represents H or R4;
• R6 represents H, C1-6 alkyl, halogen, CF3, CN, NO2, OR9, S(O)oR9, COR9, COOR9, CONR9R10, SO3R9, SO2NR9R10, tetrazolyl or R8—W;
• R7 represents C1-6 alkyl, C2-6 alkenyl or C2-6 alkynyl;
• R8 represents C2-6 alkyl, C2-6 alkenyl or C2-6 alkynyl;
• R9 represents H, C1-6 alkyl or aryl;
• R10 represents H or C1-6 alkyl;
• W represents COOH, SO3H or tetrazolyl;
• and
• o represents 0, 1 or 2;
• and the pharmaceutically compatible salts and esters thereof.